LL-37

1. LL-37 activates wnt/β-catenin signaling in rats.

   “LL-37 significantly increased the activity of the Wnt/beta-catenin pathway in OVX rats with osteoporosis”

   Animalsin OVX rats with osteoporosis

   Cathelicidin LL-37 improves bone metabolic balance in rats with ovariectomy-induced osteoporosis via the Wnt/beta-catenin pathway

   Physiological research·May 26, 2022

More on Wnt/β-catenin signaling

1. LL-37 decreases bone loss in rats.

   “LL-37 significantly reduced bone loss and pathological injury in OVX rats with osteoporosis.”

   Animalsin OVX rats with osteoporosis

   Cathelicidin LL-37 improves bone metabolic balance in rats with ovariectomy-induced osteoporosis via the Wnt/beta-catenin pathway

   Physiological research·May 26, 2022

1. LL-37 increases cellular proliferation in human cells.

   “LL-37 treatment significantly promoted the cellular proliferation of HSEs.”

   Cellstransfected human skin equivalents

   Nonviral Expression of LL-37 in a Human Skin Equivalent to Prevent Infection in Skin Wounds

   Human gene therapy·Jul 5, 2021

1. LL-37 activates mitochondrial biogenesis (PGC-1α) in human cells.

   “The anti-inflammatory effects of LL-37 are dependent upon its ability to increase mitochondrial biogenesis and to maintain mitochondrial homeostasis.”

   Cellsin HaCaT cells

   LL-37 attenuates inflammatory impairment via mTOR signaling-dependent mitochondrial protection

   The international journal of biochemistry & cell biology·Jun 28, 2014

More on Mitochondrial biogenesis (PGC-1α)

1. LL-37 decreases inflammation in human cells.

   “LL-37 was demonstrated to dramatically reduce the mRNA levels and protein secretion of inflammatory cytokines including IL-6, IL-8, IL-1α and tumor necrosis factor-α (TNF-α)”

   Cellsinduced by LPS in HaCaT cells

   LL-37 attenuates inflammatory impairment via mTOR signaling-dependent mitochondrial protection

   The international journal of biochemistry & cell biology·Jun 28, 2014

More on Inflammation